Janssen’s Rybrevant yields positive data by John Pinching | Mar 31, 2023 | News | 0 Results from trial showed a long-term response among specific lung cancer population Read More
FDA approves Janssen’s Rybrevant by Lucy Parsons | May 24, 2021 | News | 0 First targeted treatment authorised in the US for NSCLC patients with EGFR exon 20 insertion mutations Read More